- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Higher Costs Seen for Some in Congress on Health Plans
Older members of Congress and those who smoke, like Speaker John A. Boehner, could be facing much higher health insurance premiums under a new official interpretation of President Obama's health care law.
Older members of Congress and those who smoke, like Speaker John A. Boehner, could be facing much higher health insurance premiums under a new official interpretation of President Obama’s health care law.
The administration said Wednesday that the government would continue contributing to the cost of health benefits for lawmakers and thousands of Congressional employees, but that they would have to buy coverage as individuals through new state-based markets known as insurance exchanges.
Federal workers, including lawmakers, now generally get coverage through the Federal Employees Health Benefits Program, the nation’s largest employer-sponsored health insurance program. Under some of the most popular health plans, the government contributes $5,000 a year for individual coverage and $11,000 for family coverage.
Read the full story: http://nyti.ms/14o4OSv
Source: NY Times
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More
Lifestyle Interventions, Statins, Among Keys to Mitigating CVD Risk in MASLD/MASH
April 15th 2025A recent review highlights the gaps in clinical guidelines and treatment approaches for metabolic dysfunction-associated steatohepatitis (MASH) and looks ahead to the future promise of glucagon-like peptide 1 (GLP-1) receptor agonists for liver conditions.
Read More
